title: Rituximab in a patient with acute renal failure due to B-cell lymphomatous infiltration of the kidneys.
abstract: Renal failure is known to occur in lymphoproliferative disorders because of ureteral obstruction or parenchymal infiltration by disease. Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B-lymphocytes. The pharmacokinetics and metabolism of rituximab is not well established. The extent of renal clearance is not fully known, with little experience reported on the use of rituximab in patients with renal failure. We present a case where rituximab was administered to a patient with acute renal failure due to bilateral kidney infiltration by non-Hodgkin's lymphoma (NHL). The patients renal function improved on therapy, with no need for hemodialysis and there were no significant toxicities. Rituximab may be used as a treatment option for NHL patients with impaired renal function.
authors.affiliation: Department of Oncology, Soroka-University Medical Center, Beer Sheva, Israel. RitaTo@clalit.org.il
authors.forename: Margarita
authors.initials: M
authors.lastname: Tokar
authors.forename: Boris
authors.initials: B
authors.lastname: Rogachev
authors.forename: Itai
authors.initials: I
authors.lastname: Levi
authors.forename: Ronit
authors.initials: R
authors.lastname: Yerushalmi
authors.forename: Samuel
authors.initials: S
authors.lastname: Ariad
authors.forename: David B
authors.initials: DB
authors.lastname: Geffen
mesh_terms: D058186:Acute Kidney Injury / Q000209:etiology*; D000328:Adult; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D007668:Kidney / Q000473:pathology*; D016393:Lymphoma, B-Cell / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008942:Mitoxantrone / Q000627:therapeutic use; D009361:Neoplasm Invasiveness; D012074:Remission Induction / Q000379:methods; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D008942:Mitoxantrone